Poor
Needs Revision
Patient Risk:
Low
Summary
The claims are not supported by the supplied label section. Section 16 lists a product presentation and NDC number but does not address multiple manufacturers, branded versus generic products, generic sponsors, package labeling of manufacturers, or the meaning of the NDC.
Category Scores
Accurate Statements
Unsupported Statements
Enoxaparin is manufactured by multiple companies.
The supplied label identifies enoxaparin sodium injection and its product presentation but does not state that it is manufactured by multiple companies.
The manufacturer of enoxaparin can depend on the product label and strength, including whether the product is branded or generic.
The label lists a strength and product information but does not discuss manufacturer variation by strength, branding, generic status, or product label.
The same active ingredient, enoxaparin, can be supplied by different manufacturers across branded products and generic versions.
The label does not compare branded and generic products or identify different manufacturers.
Different generic sponsors may supply enoxaparin products.
The supplied label does not identify generic sponsors or state that multiple sponsors supply enoxaparin products.
The manufacturer associated with enoxaparin can vary based on the exact product name and dosage form.
The label describes a dosage form and strength but does not state that the associated manufacturer varies by product name or dosage form.
The carton or package insert may identify the manufacturer or distributing company for an enoxaparin product.
The supplied section does not state that the carton or package insert identifies a manufacturer or distributing company.
The National Drug Code (NDC) identifies the product labeler or manufacturer associated with an enoxaparin product.
The label displays an NDC number but does not explain that the NDC identifies the product labeler or manufacturer.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims are unsupported by the supplied label but do not provide dosing, administration, efficacy, contraindication, or safety instructions that could directly affect patient use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
All substantive claims about manufacturers, generic sponsors, package identification, and NDC meaning are absent from the supplied prescribing information.
Suggested Improvement
Limit the answer to information stated in the supplied label, such as the listed enoxaparin sodium injection presentation, strength, package size, NDC number, and storage conditions, or explicitly state that manufacturer information is not provided in the cited section.